TITLE

Doctor's failure to monitor possible drug reaction leads to toxicity for child and $600,000 settlement

AUTHOR(S)
Delaney, Blake J.
PUB. DATE
July 2007
SOURCE
Healthcare Risk Management;Jul2007, Vol. 29 Issue 7, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the failure of a doctor to monitor possible drug reaction in a child which led to toxicity for the patient and $600,000 settlement.
ACCESSION #
25829892

 

Related Articles

  • GP pays out £15,000 to patient.  // Pulse;1/6/2003, Vol. 63 Issue 1, p4 

    Reports on the out-of-court settlement between a general practitioner and patient over the failure of the physician to identify a serious side-effect caused by the drug prescribed in Bristol, England.

  • Billion-dollar price tag on Merck Vioxx settlement. Arnold, Matthew // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p8 

    The article reports on an estimated 1 billion dollars settlement of litigation of Merck and Co. Inc.'s Vioxx, a Cox-2 pain drug found to cause stroke and heart attacks.

  • Late Settlement Averts First Jury Test For Allegations Against General Electric's Omniscan. Gerth, Jeff // Pro Publica;1/23/2011, p2 

    It has been stated that the case that would have disclosed evidence that General Electric's Omniscan, a drug used to enhance Magnetic Resonance Imaging (MRIs), cause hundreds of kidney patients to suffer nephrogenic system fibrosis, has been settled on late Sunday night with plaintiff Loralei...

  • GSK denies it has settled thousands of lawsuits over rosiglitazone. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/12/2010, Vol. 340 Issue 7759, p1270 

    The article reports that GlaxoSmithKline is denying reports that is has settled all the approximately 13,000 lawsuits that were filed against it by patients who experienced heart attacks and strokes while taking the antidiabetic drug rosiglitazone. In May 2010, the company was reported to have...

  • PAR PHARMACEUTICAL CO.  // MondayMorning;3/11/2013, Vol. 21 Issue 9, p1 

    The article presents information on PAR Pharmaceuticals Co. that has agreed to pay 45 million U.S. dollars to settle allegations for improperly labeled and marketed prescription of the drug Megace ES to elderly patients as stated by U.S. Department of Justice. It informs that the company was...

  • 94% of patients suing Merck over rofecoxib agree to terms of company's offer. Charatan, Fred // BMJ: British Medical Journal (International Edition);3/15/2008, Vol. 336 Issue 7644, p580 

    The article reports on a decision from 94% of patients suing Merck to accept a settlement agreement which the company offered to them. The litigants sued Merck as a result of developing side effects from the company's drug Vioxx. Merck announced the $4.98 billion settlement in November of 2007,...

  • Olanzapine/risperidone.  // Reactions Weekly;8/13/2011, Issue 1364, p35 

    The article describes two cases of male patients who developed parkinsonism, tachycardia and drowsiness while undergoing olanzapine and risperidone therapy for paranoid schizophrenia.

  • Quetiapine.  // Reactions Weekly;8/13/2011, Issue 1364, p38 

    The article describes two cases of patients who developed cardiomyopathies and subsequently died after receiving treatment with quetiapine.

  • Quetiapine.  // Reactions Weekly;4/16/2011, Issue 1347, p34 

    The article describes the case of a 77-year-old woman who experienced fatal hepatoxicity during treatment with antipsychotic quetiapine for agitation and severe insomnia.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics